



Telix Pharmaceuticals Limited
ACN 616 620 369
Suite 401, 55 Flemington Road
North Melbourne
Victoria, 3051
Australia

Telix Pharmaceuticals and Grand River Aseptic Manufacturing Complete Agreement for Commercial Manufacturing of Illuccix[®]

Melbourne (Australia) and Indianapolis, IN (U.S.A.) – 31 March 2021. Telix Pharmaceuticals Limited (ASX: TLX, 'Telix', the 'Company') announces today that it has completed an agreement with contract development and manufacturing organisation (CDMO) Grand River Aseptic Manufacturing ('GRAM') to perform commercial-scale Good Manufacturing Practice (GMP) manufacturing of Telix's Illuccix[®] product (TLX591-CDx, Kit for the preparation of ⁶⁸Ga-PSMA-11) for prostate cancer imaging.

Under the terms of the Agreement, GRAM will perform advanced aseptic fill and finish services for Illuccix[®] at its facilities in Grand Rapids (Michigan, U.S.A.) for the U.S., Canada, EU and Australian markets.

Telix Americas President Dr. Bernard Lambert stated, "With commercial distribution agreements in place with major radiopharmacy networks covering over 90% of the U.S. population, we are pleased to have entered this agreement with GRAM, thus delivering a key component of our manufacturing and supply chain strategy for GMP manufacturing of Telix's first commercial product. As we prepare for the U.S. launch of Illuccix[®] it is especially reassuring to know that, subject to approval by the FDA, supply will originate from a site in Michigan, providing certainty of access for American men living with prostate cancer."

GRAM President and CEO Tom Ross added "We wish to congratulate Telix on reaching this incredible milestone. It is a great honor to support pharmaceutical innovators with fill and finish services as they work to deliver novel drug products to market. GRAM's partnership with Telix is founded on deep technical expertise and shared values that are backed by a strong quality record, world class equipment and passionate team members. I look forward to all we will accomplish together."

About Telix Pharmaceuticals Limited

Telix is a clinical-stage biopharmaceutical company developing diagnostic and therapeutic products using Molecularly Targeted Radiation. Telix is headquartered in Melbourne, Australia with international operations in Belgium, Japan, and the United States. Telix is developing a portfolio of clinical-stage products that address significant unmet medical needs in oncology and rare diseases. Telix is listed on the Australian Securities Exchange (ASX: TLX). For more information visit www.telixpharma.com and follow Telix on Twitter (@TelixPharma) and [LinkedIn](#).

Telix's lead product, Illuccix[®] (TLX591-CDx) for prostate cancer imaging, has been accepted for filing by the U.S. FDA¹, and has been granted Priority Review status by the Australian Therapeutic Goods Administration (TGA).² Telix is also progressing marketing authorisation applications for Illuccix[®] in the European Union³ and Canada.⁴ None of Telix's products have currently received a marketing authorisation in any jurisdiction.

About Grand River Aseptic Manufacturing, Inc.

[Grand River Aseptic Manufacturing, Inc. \('GRAM'\)](#), a leading parenteral contract development and manufacturing organization, delivers customized solutions to meet clients' fill and finish needs from

¹ ASX disclosure 24/11/2020.

² ASX disclosure 7/12/2020.

³ ASX disclosure 1/05/2020.

⁴ ASX disclosure 16/12/2020.

development through commercialization. With capabilities for biologics as well as controlled substances, GRAM's advanced technology and staff supports pharmaceutical development and cGMP manufacturing, analytical testing, and regulatory filing.

Telix Corporate Contact

Dr. Christian Behrenbruch
Telix Pharmaceuticals Limited
CEO
Email: chris.behrenbruch@telixpharma.com

Telix Investor Relations

Dr. David N. Cade
Telix Pharmaceuticals Limited
CBO and Head of Investor Relations
Email: david.cade@telixpharma.com

Important Information

This announcement does not constitute an offer to sell, or a solicitation of an offer to buy, securities in the United States, or in any other jurisdiction in which such an offer would be illegal. The securities referred to herein have not been and will not be registered under the United States Securities Act of 1933 (the "U.S. Securities Act"), or under the securities laws of any state or other jurisdiction of the United States and may not be offered or sold within the United States, unless the securities have been registered under the U.S. Securities Act or an exemption from the registration requirements of the U.S. Securities Act is available. None of the technologies or products described in this document have received a marketing authorisation in any jurisdiction. This announcement has been authorised for release by Dr Christian Behrenbruch, Managing Director and Chief Executive Officer.